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Introduction
The potential risks associated with cardiovascular imaging (CVI) have
recently been debated, partly triggered by the rapid increase in the
use of imaging procedures and new imaging modalities such as
cardiac computed tomography (CT).1,2 The discussion has mainly
focused only on a single-risk aspect such as radiation.3 However,
the various procedures have several risks: stressors, contrast
agents, invasiveness, radiation, etc. Even more important, the test
must be related to the benefit of performing or not performing the
test with the risk and drawbacks associated with the disease remain-
ing undetected.
We aimed to create a balanced analysis of immediate, short- and
long-term risks associated with CVI in relation to the natural
course of coronary artery disease (CAD) and to therapeutic inter-
ventions. The imaging tests for CAD were selected, since many
CVI tests are commonly used. We analysed: (i) the risk of major
cardiac events (MCEs) for each component of imaging test; (ii) the
upper limit for each risk, in order to avoid underestimation of a
risk; (iii) composite risks calculated for selected common diagnostic
tests for CAD; (iv) the risks compared with the risk of the disease
itself, to assess the potential benefits of tests; and (v) comparison
with risks in regular life activities and that associated with trivial long-
term prophylactic interventions such as aspirin use.
This analysis is based on the data available from the literature. Data
for risks related to some of the procedures are quite limited, for some
variable, and for some of limited quality. Still we sought to present risk
estimations from all the procedures using reliable studies and data-
bases available from an extensive search of the literature. The
detailed information about risk assessments is shown in Supplemen-
tary material.
Analysis of risks
Definitions
In the literature, risks are described in many different ways, e.g. ‘fatal,
major, serious, less severe, and milder’. In the present analysis, we use
‘fatal’, when presented as such in the literature. ‘MCEs’, often used in
the investigations, are presented quoting the descriptions of the cita-
tions. The degree of seriousness for ‘less serious or minor adverse or
side effects’ vary significantly in the citations referred. In this analysis,
they are defined as complications or side effects that are not life
threatening. ‘Adverse events (AEs) (serious and less serious) and
adverse drug reactions’ in relation to drug administration are
described according to the WHO definitions.4
Stress tests
Dynamic exercise and different pharmacological stress agents includ-
ing vasodilators (adenosine, dipyridamole, selective A2A receptors
agonists) and inotropic-chronotropic agents (dobutamine) are
employed. The overall hard events rate of dynamic exercise has
been reported to be in the range of 1.2–8.6/10 000 tests, depending
on the referring population.5,6 The overall hard event rate of pharma-
cological stress with dipyridamole or adenosine is comparable with
that of exercise,7,8 but minor side effects are more common. Recently,
A2A selective agonists have been approvedas stressors.The incidence
of serious AEs and side effects appears significantly lower than with
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adenosine.9 The complication rate with dobutamine, which is used
commonly with stress echocardiography is higher than that reported
for other stressors: One severe AE in 335 tests has been reported in
a recent meta-analysis.10,11 For the purpose of this study, we used a
fatal event rate of 1/20 000 for exercise and 1/10 000 for pharmaco-
logical stressors.
Imaging procedures
Cardiac magnetic resonance imaging
Strong static magnetic field as such is unlikely to cause significant
adverse biological effects. RF energy applied to the body may be re-
sponsible for tissue heating.12 Some metallic devices, e.g. pacemaker
leads, may potentially induce excessive local heating as well as
arrhythmias.13 Gradient magnetic fields could stimulate nerves and
muscles, occasionally causing discomfort14 but current cardiac mag-
netic resonance imaging (CMRI) systems typically operate below
nerve stimulation levels. Quickly changing magnetic fields may gener-
ate electrical currents in electrically conductive devices with poten-
tial risk of arrhythmia induction in patients with pacemaker leads.13
Ferromagnetic objects, including cerebral aneurysm clips, drug infu-
sion pumps, cardiac pacemakers/defibrillators, accidentally intro-
duced into a CMRI suite are quickly attracted towards the magnet
and has been cause of significant injuries and even death of patients
and CMRI operators. Significant increase of DNA double-strand
breaks have been detected after routine 1.5 T cardiac MR examin-
ation15,16 but obviously more information about this phenomenon
is needed to make any numerical estimation about this risk.
In this paper, we estimated accidents in 0.07/10 000 examinations
and 0.2/10 000 other serious AEs, including burns, arrhythmias in
CMRI studies. Since no data are currently available about the clinical
events caused by MR-induced DNA damage, this risk was not
included.
Echocardiography
Biological effects of diagnostic ultrasound have been documented in
experimental studies conducted on molecular, cellular and animal
level.17 The effects depend on the characteristics of the sound
wave, sensitivity of exposed tissue, and time duration of exposure.
The effects may broadly be classified into thermal and mechanical
effects. With current diagnostic ultrasound technology, biological
effects are unlikely to be caused directly by tissue heating.18
Among possible mechanical effects of ultrasound, a potential risk is
cavitation: formation and rhythmic oscillation of microbubbles pro-
duced from gasses dissolved in living tissue. The mechanical index
has been developed as predictor of acoustic cavitation and is dis-
played as a safety parameter on modern ultrasound scanners. Capil-
lary rupture can be demonstrated when tissues containing gas-filled
contrast agents are exposed to ultrasound,19 but so far there is no
evidence of significant health risk from exposure to medical ultra-
sound for patients or clinical staff members.
Coronary angiography
Diagnostic invasive coronary angiography (CAG), like most invasive
procedures, may cause serious complications.20,21 Major complica-
tions of 1–2% are reported (Table 1), the likelihood of major
complications increasing significantly with the severity of the under-
lying disease. Important predictors of major complications include
shock, acute myocardial infarction of,24 h, unstable angina, cardio-
myopathy, renal insufficiency, heart failure, and high age. Patients
undergoing CAG in an emergency setting are at greatest risk for com-
plications. The skill and experience of the operator and the catheter-
ization laboratory staff, as well as the peri-procedural management
and low-profile catheters are also important factors. Currently, the
transradial approach decreases entry site complications as compared
with the femoral approach.
In the current analysis, the acute risk of death by CAG was
estimated to be 8/10 000 studies and the rate of serious AEs
177/10 000.20,21
Contrast agents and tracers
Contrast agents for cardiac computed
tomography and invasive coronary
angiography (iodinated)
Computed tomography and invasive CAG requires injection of an
iodinated contrast agent. Adverse events after use of contrast
media include local effects (extravasation), acute or delayed reac-
tions and contrast-induced nephropathy. Extravasation occurs in
0.2% of procedures when a power injector is used22 and may
lead to severe damage, including compartment syndrome. Mild
general reactions occur in 0.4% of patients and serious reactions, in-
cluding pulmonary oedema, severe hypotension, and loss of con-
sciousness occur in 0.04%23 with non-ionic contrast agents.
The most prominent risk of iodinated contrast agents is nephro-
toxicity, rare in patients without a history or symptoms of renal
disease. The incidence of kidney injury was 1.3% after percutaneous
coronary intervention.24 Nephropathy rates were substantially
lower for intravenous compared with intra-arterial injections (1.1
and 1.8%, respectively).24 –26 The additional mortality of patients
with clinically significant kidney failure was reported as high as
14–15.8%.24– 27
For the purpose of this study, weestimated the rate of death due to
acute general reactions for contrast agents as 0.059/10 000 and long-
term risk due to nephropathy to be 6.6/10 000 for intravenous and
7.6/10 000 for intra-arterial administration. The rate of serious
acute AEs was estimated to be 4.06 and long-term events 79.0 per
10 000 studies.
Contrast agents for echocardiography
Contrast agents in echocardiography are used for cardiac chamber
opacification, in particular to improve the endocardial border of
the left ventricle,28 and evaluation of myocardial perfusion. The use
of contrast agents improves diagnostic accuracy and reproducibility
of both rest and stress echocardiography, including left ventricular
volumes, ejection fraction, and wall motion assessment.28,29
In the present analysis, we used a risk of serious AEs as 3/10 000
and the risk of death 0.1/10 000 after echo-contrast administration
as suggested by the overall post-marketing experience with a perflut-
ren lipid microsphere (Definity).30 In our estimations, we assumed
that contrast agents have been used in stress echo examinations.
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Contrast agents for cardiac magnetic
resonance imaging
When CMR contrast agents are used in doses producing equal at-
tenuation as iodinated contrast agents, the risk of renal dysfunction
is similar to that caused by iodinated agents.31,32 Furthermore,
gadolinium-based contrast agents are associated with the develop-
ment of nephrogenic systemic fibrosis (NSF). Nephrogenic systemic
fibrosis is potentially a lethal disease but it has never been seen in
patients with normal kidney function.33 Although rare, acute allergy-
like reactions occur after intravenous gadolinium-based contrast
agents in0.03–0.2%ofpatients.34,35 Most reactions aremild (rash, ur-
ticaria). Severe, life-threatening reactions (respiratory distress, car-
diopulmonary arrest) are extremely rare: only 33 reactions after
687 000 doses36 and very few of them fatal reactions.37
In the present analysis, we estimated a risk for acute fatal events to
be 1/1 000 000 studies and the rate of acute severe AEs 4.8/100 000
studies. Since the literature does not present hard data for the calcu-
lation of a long-term nephrotoxic risk, we used the same risk factors
as those for CT contrast agents. Thus, the estimated long-term death
rate was 6.6/10 000 due to nephrotoxicity and 0.33/10 000 due to
NSF. The former risk may be overestimated due to fact that
smaller amounts of contrast materials are used.
Tracers for radionuclide imaging
Radiotracers for cardiac imaging (SPECT or PET) have good
safety profiles: 2–6 AEs/million for 99mTc-sestamibi/-tetrofosmin
injections.38 –40 The risk of AEs is even lower with 201thallium. No
serious AEs have been reported after PET tracers. The overall the
prevalence of AEs following radiopharmaceutical administration is
.1000 times lower than that after ordinary pharmaceuticals and
diagnostic contrast media38 –40 probably related to the very small
amount of tracer injected.
For the current risk analysis, the risk of death was considered to be
negligible and the rate of serious AEs 0.06/10 000 studies.
Ionizing radiation
The harmful effects of ionizing radiation are classified into stochastic
effects, which are due to radiation-induced mutations, and determin-
istic effects, which are due to radiation-induced cell death. Stochastic
effects are the primary concern in cardiac imaging.3
Estimation of the risk from ionizing radiation is difficult, since no
prospective trials focusing on the AEs of radiation with doses used
in diagnostic procedures have ever been performed. Risks related
to low doses are derived by linear extrapolation, mainly from
epidemiological studies of atom bomb survivors in Hiroshima and
Nagasaki.41 Currently, one in three women and one in two men in
the USA will develop cancer in his or her lifetime.42 Since this is so
much higher than any estimated effect of medical radiation, the po-
tential minute increase in cancer due to radiation is extremely difficult
to detect.
The radiation doses of cardiac examinations are displayed in
Table 2. Recent software and hardware implementation may have
reduced the patient exposition but could not be taken into account
here. Since the risk due to radiation depends on several factors in
populations, the European Commission Radiation protection guide-
line43 (2008) makes cautious statement about using collective effect-
ive dose estimates in assessing radiation risks to patients by simple
application of the nominal probability coefficients derived for a
general population. Being aware of these limitations and since no
better estimates are available, for the purpose of this study, we
used the estimated risk by ICRP,44 in which 10 mSv would translate
to 5 additional fatal cancers/10 000 patients.
The composite risks of diagnostic tests
The risks can be divided into acute and long-term risks. The acute AEs
include allergic reactions of contrast agents, accidents during the scan
and arrhythmias induced by stressors as the more important risks.
Long-term AEs include malignancies and contrast-induced nephro-
pathy as the more important risks. The risks of acute and late
events were calculated separately and then pooled together to
create a composite risk. With the numerous variations of each test,
the selected tests are serving as examples for the composite risk
profile for typical imaging of CAD.
All non-invasive tests show a very low risk of acute death (Figure 1)
and stressors imply the highest risk for death, not the procedures
themselves or the contrast agents. The acute risk of an invasive test
is related to the procedure itself. When taking into account also
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Table 1 Complication rates/10 000 examinations during diagnostic cardiac catheterization
Death MI Stroke Ventricular arrhythmia Vascular Contrast reaction Total
8 5 7 10 20 70 177
MI, myocardial infarction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Typical effective doses of the most common
cardiac imaging procedures
Procedure Effective doses (mSv)
Calcium score 1–2
CT angiography 3–20 (mean 7)
Tl-201 stress + rest SPECT 22
Tc-99 m tetrofosmin or sestamibi
stress + rest SPECT
10
PET perfusion stress + rest
(Rb-82, N-13 ammonia, O-15 water)
2.0–2.7
FDG PET viability 4.9
Invasive CAG 2–23 (mean 7)
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the long-term risks, the picture is somewhat changed (Figure 2). The
risks of a fatal event by contrast agents and by radiation exposure are
more important using non-invasive tests. The estimated risks of acute
and long-term serious AEs due to an imaging procedure are shown in
Figure 3.
Comparison of risks of diseases, therapies
and activities of daily life in healthy subjects
In Figure 4, the composite long-term risks of a fatal event due to
imaging are compared with the risks of CAD, aspirin medication
and the risks of daily-life activities. Based on SCORE,45 an asymptom-
atic male at the age of 50–60 years with more than one risk factor for
atherosclerosis has a 10-year risk of cardiovascular death 1000/10
000. In a symptomatic population, the risk will definitely be higher and
dependent on the severity of disease. The life-time risk of fatal bleed-
ing by aspirin medication is 140/10 000.46 The life-time risk of dying in
a fatal motor vehicle accident is 119/10 000.47 The corresponding
risks of fatal accidents for pedestrians, by drowning and by bicycling,
are 16, 9 and 2 per 10 000 subjects, respectively. The risk of fatal
bleeding due to aspirin is about seven times higher than the risk of
an invasive imaging test and 14–280 higher than any non-invasive
imaging test. Correspondingly, the risk of death due to CAD even
within 10 years is about 50 times higher than the risk of an invasive
imaging and 100–2000 times higher than any non-invasive imaging
procedure.
Discussion
To the best of our knowledge, this is the first study that has analysed
acute and long-term composite risks related to CVI. Our analysis
shows several important findings: stress agents are relatively major
contributors to acute risks related to CVI. However, in absolute
figures, the risk is small. In invasive tests, the procedure itself is the
most important risk factor. For long-term risks of fatal events, the
Figure 2 Estimated risk of acute and long-term death due to an
imaging procedure.
Figure 3 Estimated risk of acute and long-term serious adverse
events due to an imaging procedure.
Figure1 Estimatedriskofacutedeathduetoan imagingprocedure.
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risks of contrast agents and the radiation risk have high impact on the
composite risk of the procedure. The risks of non-fatal events are
mostly related to stressors and contrast agents.
It is to be noted that the life-time risk of imaging procedures for
fatal events is small as compared with the general risk of fatal
cardiac events by CAD both in asymptomatic and symptomatic
populations. Although the risk of aspirin therapy has no clear link
with the risks of imaging test, we used that for a comparison to get
an idea about the scale of various risks. Aspirin therapy is commonly
suggested as a safe therapy for patients with coronary atherosclerosis
and is used liberally in patients with mild and asymptomatic CAD. We
found that the risk of imaging tests at the highest is less than one-
seventh of the life-time risk of fatal bleeding by aspirin. The risk asso-
ciated with revascularization is of course markedly higher than any
medical or diagnostic intervention but the benefit is also well docu-
mented when used appropriately.
The risk associated with imaging procedures is small as compared
also with other risks. In patients with suspected or known CAD, the
risks from the disease left untreated is obviously much higher and
increases with the severity of the disease. Therefore, the relative
risk from the natural course of the disease as compared with the
risk of imaging is even more striking. The relative low risk of
imaging is further emphasized when comparing risks of imaging
tests with daily-life activities and imaging risk appears in the same
range as that related to walking, swimming, or bicycling.
The benefit of imaging, both in known and suspected CAD, is pres-
ently intensively debated: What is the best algorithm for demonstrat-
ing CAD in order to offer a therapeutic intervention? The economic
consequences of the recent increases in number of imaging proce-
dures also play a significant role in the debate. There is no doubt
that benefit of imaging is not only achieved, but indispensable for
patients, both to offer optimal therapeutic interventions and to elim-
inate the fear and anxiety in symptomatic subjects without CAD.
Conclusions
The CVI tests are all related to small but detectable risks. Different
components of imaging tests contribute to the acute and long-term
risks. The composite risks of imaging tests are in the same range as
the risks of common daily-life activities and are only a minor fraction
of the risk of CAD or common therapeutic or prophylactic medical
interventions.
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Supplementary material is available at European Heart Journal online.
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